ES2285741T3 - Polimeros polianionicos como adyuvantes para la inmunizacion mucosa. - Google Patents
Polimeros polianionicos como adyuvantes para la inmunizacion mucosa. Download PDFInfo
- Publication number
- ES2285741T3 ES2285741T3 ES97950021T ES97950021T ES2285741T3 ES 2285741 T3 ES2285741 T3 ES 2285741T3 ES 97950021 T ES97950021 T ES 97950021T ES 97950021 T ES97950021 T ES 97950021T ES 2285741 T3 ES2285741 T3 ES 2285741T3
- Authority
- ES
- Spain
- Prior art keywords
- animals
- adjuvant
- groups
- acid
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003053 immunization Effects 0.000 title description 37
- 238000002649 immunization Methods 0.000 title description 37
- 229920000642 polymer Polymers 0.000 title description 37
- 239000002671 adjuvant Substances 0.000 claims abstract description 260
- 229960005486 vaccine Drugs 0.000 claims abstract description 167
- 239000002253 acid Substances 0.000 claims abstract description 15
- 229920000447 polyanionic polymer Polymers 0.000 claims abstract description 15
- 230000006698 induction Effects 0.000 claims abstract description 11
- 125000000129 anionic group Chemical group 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 4
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000427 antigen Substances 0.000 claims description 121
- 108091007433 antigens Proteins 0.000 claims description 121
- 102000036639 antigens Human genes 0.000 claims description 121
- 238000002360 preparation method Methods 0.000 claims description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 230000003252 repetitive effect Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 4
- 230000016379 mucosal immune response Effects 0.000 abstract description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- LZSNGCBGVADDSH-UHFFFAOYSA-N (2-ethenylphenyl) hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1C=C LZSNGCBGVADDSH-UHFFFAOYSA-N 0.000 abstract 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 abstract 1
- QNIRRHUUOQAEPB-UHFFFAOYSA-N 2-(prop-2-enoylamino)butane-2-sulfonic acid Chemical compound CCC(C)(S(O)(=O)=O)NC(=O)C=C QNIRRHUUOQAEPB-UHFFFAOYSA-N 0.000 abstract 1
- SQVSEQUIWOQWAH-UHFFFAOYSA-N 2-hydroxy-3-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)OCC(O)CS(O)(=O)=O SQVSEQUIWOQWAH-UHFFFAOYSA-N 0.000 abstract 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 abstract 1
- UYRCWWINMMLRGJ-UHFFFAOYSA-N 3-ethenoxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC=C UYRCWWINMMLRGJ-UHFFFAOYSA-N 0.000 abstract 1
- IRQWEODKXLDORP-UHFFFAOYSA-N 4-ethenylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=C)C=C1 IRQWEODKXLDORP-UHFFFAOYSA-N 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 abstract 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 abstract 1
- VEWLDLAARDMXSB-UHFFFAOYSA-N ethenyl sulfate;hydron Chemical compound OS(=O)(=O)OC=C VEWLDLAARDMXSB-UHFFFAOYSA-N 0.000 abstract 1
- 150000002170 ethers Chemical group 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 150000002334 glycols Chemical group 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- RAGRPVMAKIWULP-UHFFFAOYSA-N n'-ethenylbutanediamide Chemical compound NC(=O)CCC(=O)NC=C RAGRPVMAKIWULP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 299
- 241001465754 Metazoa Species 0.000 description 237
- 238000009472 formulation Methods 0.000 description 224
- 210000004027 cell Anatomy 0.000 description 133
- 239000000243 solution Substances 0.000 description 130
- 239000006285 cell suspension Substances 0.000 description 128
- 229920002125 Sokalan® Polymers 0.000 description 96
- 230000000890 antigenic effect Effects 0.000 description 95
- 238000003860 storage Methods 0.000 description 76
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- 210000004072 lung Anatomy 0.000 description 50
- 241000711404 Avian avulavirus 1 Species 0.000 description 48
- 229920001577 copolymer Polymers 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- 230000003393 splenic effect Effects 0.000 description 41
- 239000000725 suspension Substances 0.000 description 40
- 210000000952 spleen Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 210000005265 lung cell Anatomy 0.000 description 34
- 230000036039 immunity Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 239000000178 monomer Substances 0.000 description 24
- 239000008363 phosphate buffer Substances 0.000 description 22
- 239000008055 phosphate buffer solution Substances 0.000 description 21
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 18
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 18
- 238000002156 mixing Methods 0.000 description 18
- 229940031439 squalene Drugs 0.000 description 18
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 18
- 229910021642 ultra pure water Inorganic materials 0.000 description 17
- 239000012498 ultrapure water Substances 0.000 description 17
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 16
- 239000004584 polyacrylic acid Substances 0.000 description 16
- 230000002685 pulmonary effect Effects 0.000 description 16
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 239000002502 liposome Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 14
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 208000037797 influenza A Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 9
- 229960002796 polystyrene sulfonate Drugs 0.000 description 9
- 239000011970 polystyrene sulfonate Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 8
- VMSBGXAJJLPWKV-UHFFFAOYSA-N 2-ethenylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=C VMSBGXAJJLPWKV-UHFFFAOYSA-N 0.000 description 7
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229960000380 propiolactone Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 p (A-c-VBS) Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9622159.3A GB9622159D0 (en) | 1996-10-24 | 1996-10-24 | Polyanionic polymers as adjuvants for mucosal immunization |
| GB9622159 | 1996-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2285741T3 true ES2285741T3 (es) | 2007-11-16 |
Family
ID=10801896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97950021T Expired - Lifetime ES2285741T3 (es) | 1996-10-24 | 1997-10-23 | Polimeros polianionicos como adyuvantes para la inmunizacion mucosa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6610310B2 (enExample) |
| EP (1) | EP0934077B1 (enExample) |
| JP (1) | JP4344014B2 (enExample) |
| AT (1) | ATE360440T1 (enExample) |
| AU (1) | AU717349B2 (enExample) |
| BR (1) | BR9712436A (enExample) |
| CA (1) | CA2269780C (enExample) |
| DE (1) | DE69737658T2 (enExample) |
| ES (1) | ES2285741T3 (enExample) |
| GB (1) | GB9622159D0 (enExample) |
| WO (1) | WO1998017310A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
| US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
| US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| CN100570365C (zh) * | 2002-11-14 | 2009-12-16 | 斯克里普斯研究所 | 抗体或嗜中性粒细胞介导的臭氧产生 |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| JP4860109B2 (ja) * | 2003-12-26 | 2012-01-25 | バイオリーダース・コーポレイション | ポリガンマグルタミン酸を含む免疫増強用組成物 |
| DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| US20090017064A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
| FR2922767B1 (fr) | 2007-10-24 | 2009-12-18 | Seppic Sa | Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant. |
| US9056909B2 (en) * | 2007-11-06 | 2015-06-16 | Zoetis Services Llc | Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine |
| EP2062594A1 (en) | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| TW201010719A (en) * | 2008-08-19 | 2010-03-16 | Wyeth Corp | Immunological composition |
| GB0907989D0 (en) | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| WO2011041003A2 (en) | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| US20110110980A1 (en) * | 2009-09-02 | 2011-05-12 | Wyeth Llc | Heterlogous prime-boost immunization regimen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| US20130310462A1 (en) | 2010-08-04 | 2013-11-21 | Tixupharma | Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair |
| CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
| KR101584871B1 (ko) | 2010-09-10 | 2016-01-22 | 와이어쓰 엘엘씨 | 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체 |
| HUE033072T2 (hu) | 2010-12-22 | 2017-11-28 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| DE102010056566A1 (de) * | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Kontinuierliches Verfahren zur Veresterung Säuregruppen tragender Polymere |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| CA2865745C (en) | 2012-03-09 | 2018-01-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| RU2672053C2 (ru) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Способ гликоконъюгации |
| CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| CA2925281C (en) | 2013-09-25 | 2022-05-03 | Zoetis Services Llc | Pcv2b divergent vaccine composition and methods of use |
| KR20190049940A (ko) | 2015-02-19 | 2019-05-09 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
| KR102143534B1 (ko) | 2015-05-04 | 2020-08-12 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| KR102724939B1 (ko) * | 2016-06-17 | 2024-11-01 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형 |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| CA3093709C (en) | 2018-03-16 | 2024-03-26 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| CN109134724A (zh) * | 2018-07-24 | 2019-01-04 | 石家庄哈顿生物技术有限公司 | 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法 |
| CA3155669A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4567042A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| ES2052685T3 (es) * | 1987-03-17 | 1994-07-16 | Akzo Nv | Metodo para producir un adyuvante libre. |
| US5242686A (en) * | 1990-11-07 | 1993-09-07 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
| EP0532833A1 (en) * | 1991-05-28 | 1993-03-24 | Miles Inc. | Vaccine for equine rhinopneumonitis |
| BE1008977A5 (fr) * | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
-
1996
- 1996-10-24 GB GBGB9622159.3A patent/GB9622159D0/en active Pending
-
1997
- 1997-10-23 EP EP97950021A patent/EP0934077B1/en not_active Expired - Lifetime
- 1997-10-23 BR BR9712436-2A patent/BR9712436A/pt not_active Application Discontinuation
- 1997-10-23 DE DE69737658T patent/DE69737658T2/de not_active Expired - Lifetime
- 1997-10-23 US US09/297,214 patent/US6610310B2/en not_active Expired - Lifetime
- 1997-10-23 JP JP51897598A patent/JP4344014B2/ja not_active Expired - Lifetime
- 1997-10-23 CA CA002269780A patent/CA2269780C/en not_active Expired - Lifetime
- 1997-10-23 AU AU53133/98A patent/AU717349B2/en not_active Expired
- 1997-10-23 AT AT97950021T patent/ATE360440T1/de not_active IP Right Cessation
- 1997-10-23 WO PCT/EP1997/005861 patent/WO1998017310A2/en not_active Ceased
- 1997-10-23 ES ES97950021T patent/ES2285741T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69737658D1 (de) | 2007-06-06 |
| JP2001507336A (ja) | 2001-06-05 |
| EP0934077A2 (en) | 1999-08-11 |
| CA2269780C (en) | 2008-12-02 |
| AU5313398A (en) | 1998-05-15 |
| JP4344014B2 (ja) | 2009-10-14 |
| US6610310B2 (en) | 2003-08-26 |
| WO1998017310A3 (en) | 1998-06-18 |
| EP0934077B1 (en) | 2007-04-25 |
| US20030021793A1 (en) | 2003-01-30 |
| WO1998017310A2 (en) | 1998-04-30 |
| DE69737658T2 (de) | 2008-01-31 |
| AU717349B2 (en) | 2000-03-23 |
| ATE360440T1 (de) | 2007-05-15 |
| CA2269780A1 (en) | 1998-04-30 |
| BR9712436A (pt) | 2000-10-24 |
| GB9622159D0 (en) | 1996-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6610310B2 (en) | Polyanionic polymers as adjuvants for mucosal immunization | |
| US10369229B2 (en) | Methods and compositions for liposomal formulation of antigens and uses thereof | |
| KR100353496B1 (ko) | 하이드로겔마이크로캡슐화백신 | |
| US6126938A (en) | Methods for inducing a mucosal immune response | |
| EP0804283B1 (en) | Aqueous solvent encapsulation method and microcapsules | |
| US6531156B1 (en) | Aqueous solven encapsulation method, apparatus and microcapsules | |
| Bramwell et al. | Particulate delivery systems for vaccines | |
| AU690567B2 (en) | Hydrogel microencapsulated vaccines | |
| ES2369550T3 (es) | Formulación de adyuvante para administración en mucosas. | |
| JP2010105968A (ja) | カチオン性ナノゲルを用いる粘膜ワクチン | |
| WO1995002416A9 (en) | Hydrogel microencapsulated vaccines | |
| EP0789590B1 (en) | Chitosan induced immunopotentiation | |
| Mangal et al. | Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system (s) administered intranasally | |
| ES2216242T3 (es) | Encapsulacion de vacuna subunitaria contra el virus del herpes bovino tipo 1 en base a un disolvente acuoso. | |
| ES2235489T3 (es) | Uso de polimeros de acido hialuronico para la administracion por las mucosas de antigenos y coadyuvantes de vacunas. | |
| MXPA99003830A (en) | Polyanionic polymers as adjuvants for mucosal immunization | |
| JPH06503555A (ja) | ワクチン | |
| KR100664466B1 (ko) | 경구용 백신 운반을 위한 미세입자 및 이들의 제조방법 | |
| Sharma | Development and evaluation of novel biodegradable nanoparticles for vaccine delivery | |
| HK1001965B (en) | Aqueous solvent encapsulation method and microcapsules | |
| WO2001089561A1 (fr) | Vaccins contre le sida |